We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Target Sequence Capture Panel Eases Detection of Viruses in Patient Samples

By LabMedica International staff writers
Posted on 14 Oct 2015
A recently developed targeted sequence capture panel, ViroCap, which was designed to enrich nucleic acid from DNA and RNA viruses that infect vertebrate hosts, allowed the rapid detection of unknown viruses in patient samples.

Metagenomic shotgun sequencing (MSS) is an important tool for characterizing viral populations. More...
It is culture-independent, requires no a priori knowledge of the viruses in the sample, and may provide useful genomic information. However, MSS can lack sensitivity and may yield insufficient data for detailed analysis. To solve these problems investigators at Washington University School of Medicine (St. Louis, MO, USA) have created a targeted sequence capture panel, ViroCap, designed to enrich nucleic acid from DNA and RNA viruses from 34 families that infect vertebrate hosts.

During the development of ViroCap the investigators submitted consolidated target sequences to 454 Roche NimbleGen (Madison, WI, USA) for capture library design and 454 synthesis. This computational approach condensed nearly one billion base pairs (bps) of viral reference sequence into less than 200 million bps of unique, representative sequence suitable for targeted sequence capture. These sequences were used as probes to scoop up viruses in patient samples that were a genetic match. The matched viral material was analyzed using high-throughput genetic sequencing.

The investigators used ViroCap to analyze two sets of samples, one derived from samples submitted to a diagnostic virology laboratory and one derived from samples collected in a study of fever in children. They reported detecting 14 and 18 viruses in the two sets, respectively, comprising 19 genera from 10 families. Compared to standard genomics-based detection methods, 52% more viruses were found by the ViroCap method.

"With this test, you do not have to know what you are looking for," said senior author, Dr. Gregory Storch, professor of pediatrics at Washington University School of Medicine. "It casts a broad net and can efficiently detect viruses that are present at very low levels. We think the test will be especially useful in situations where a diagnosis remains elusive after standard testing or in situations in which the cause of a disease outbreak is unknown."

Details were published in the September 22, 2015, online edition of the journal Genome Research.

Related Links:

Washington University School of Medicine
454 Roche NimbleGen



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.